PET Imaging in Patients With Suspected Cardiac Sarcoidosis
PET Imaging in Patients With Suspected Cardiac Sarcoidosis
Gallium-68 DOTATATE is a radioactive tracer, a type of imaging drug that is labeled with a
 radioactive tag and injected into the body, which is approved by the U.S. Food and Drug
 Administration (FDA) to diagnose certain tumors. The study will see how the tracer is taken
 up in your heart before and after treatment using an imaging scan called Positron Emission
 Tomography / Computed Tomography (PET/CT). Investigators are doing this research study to
 find out if DOTATATE can help doctors diagnose people with cardiac (heart) sarcoidosis better
 as well as serve as a follow-up monitoring tool for a response to therapy.
Inclusion Criteria:

 1. Participants will be ≥ 18 years of age

 2. History of biopsy-proven sarcoidosis OR suspected sarcoidosis based on standard
 clinical imaging (e.g. FDG PET/CT, MRI) without biopsy confirmation

 3. Clinical suspicion of cardiac involvement defined as the presence of any of the
 following:

 1. High degree A-V nodal block

 2. Complete bundle branch block

 3. Reduced left or right ventricular systolic fusion

 4. Any cardiac arrhythmia

 5. Chest pain, dyspnea or syncope without clear etiology

 4. FDG PET/CT scan demonstrating abnormal myocardial FDG uptake

 5. Participants must be informed of the investigational nature of this study and be
 willing to provide written informed consent and participate in this study in
 accordance with institutional and federal guidelines prior to study-specific
 procedures

 Exclusion Criteria:

 1. Females who are pregnant or breast feeding at the time of screening will not be
 eligible for this study; a urine pregnancy test will be performed in women of
 child-bearing potential at screening.

 2. History of neuroendocrine tumors

 3. Currently taking the medication Octreotide

 4. Currently on total parenteral nutrition (TPN)

 5. Inability to tolerate imaging procedures in the opinion of an investigator or treating
 physician

 6. Any current medical condition, illness, or disorder as assessed by medical record
 review and/or self-reported that is considered by a physician investigator to be a
 condition that could compromise participant safety or successful participation in the
 study